Vaccine Therapy for Patients with Melanoma

ONCOLOGY

Volumn 13, Issue 11, 1999, Pages 1561-1574

  Haigh, Philip I ^b   Difronzo, L Andrew ^b   Gammon, Guy ^b   Morton, Donald L ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE;

HUMAN; IMMUNOLOGY; MELANOMA; REVIEW; SKIN TUMOR;

CANCER VACCINES; HUMANS; MELANOMA; SKIN NEOPLASMS;

EID: 0033220035     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (82)

1. Morton DL, Wanek L, Nizze JA et al: Improved long-term survival after lymphadenectomy of melanoma metastatic to regional nodes. Ann Surg 214:491-501, 1991.
2. Kirkwood JM, Strawderman MH, Ernstoff MS, et al: Interferon-alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group trial EST 1684. J Clin Oncol 14:7-17, 1996.
3. Kirkwood JM, Ibrahim J, Sondak V, et al: Role of high-dose interferon in high risk melanoma: Preliminary results of the E1690/S9111/ C9190 US Intergroup postoperative adjuvant trial of high and low-dose interferon-alfa-2b in resected high-risk primary or regionally lymph node metastatic melanoma in relation to 10-year updated results of E1684. Presented at the Symposium on Advances in Biology and Treatment of Cutaneous Melanoma, Boston, Massachusetts, November 7, 1998.
4. Hill GJ, Krementz ET, Hill HZ: Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma: IV. Late results after complete response to chemotherapy. Cancer 53:1299, 1984.
5. Legha SS, Ring S, Bedikan A, et al: Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine, and dacarbazine (CVD) and biotherapy using interleukin-2 and interpheron-alfa. Ann Oncol 7:827-835, 1996.
6. McClay EF, Mastrangelo MJ, Berd D, et al: Effective combination chemo/hormonal therapy for malignant melanoma: Experience with three consecutive trials. Int J Cancer 50:553-556, 1992.
7. Shrayer DP, Bogaars H, Hearing VJ, et al: Immunization of mice with irradiated melanoma tumor cells transfected to secrete lymphokines and coupled with IL-2 or GM-CSF therapy. J Exp Ther Oncol 1:126-133, 1996.
8. Kobayashi M, Kobayashi H, Pollard RB, et al: A pathogenic role of Th2 cells and their cytokine products on the pulmonary metastasis of murine B16 melanoma. J Immunol 160:5869-5873, 1998.
9. Wallich R, Bulbuc N, Hammerling GJ, et al: Abrogation of metastatic properties of tumour cells by de novo expression of H-2K antigens following H-2 gene transfection. Nature 315:301-305, 1985.
10. Restifo NP, Esquivel F, Asher AL, et al: Defective presentation of endogenous antigens by a murine sarcoma: Implications for the failure of an anti-tumor immune response. J Immunol 147:1453-1459, 1991.
11. Pardoll DM: Cancer vaccines. Nat Med 4:525-531, 1998.
12. Topalian S, Solomon D, Rosenberg SA: Tumour-specific lysis by lymphocytes infiltrating human melanomas. J Immunol 142:3714-3720, 1989.
13. Maeurer MJ, Storkus WJ, Kirkwood JM, et al: New treatment options for patients with melanoma: Review of melanoma-derived T-cell epitope-based peptide vaccines. Melanoma Res 6:11-24, 1996.
14. Morton DL, Barth A: Vaccine therapy for malignant melanoma. CA Cancer J Clin 46:225-244, 1996.
15. Ollila DW, Kelley MC, Gammon G, et al: Overview of melanoma vaccines: Active specific immunotherapy for melanoma patients. Semin Surg Oncol 14:328-336, 1998.
16. Trau H, Kopf AW, Riegel DS, et al: Regression in malignant melanoma. J Am Acad Dermatol 8:363-368, 1983.
17. Morton DL, Nizze A, Hoon D, et al: Improved survival of advanced stage IV melanoma following active immunotherapy: Correlation with immune response to melanoma vaccine (abstract). Proc Am Soc Clin Oncol 12:391, 1993.
18. Morton DL, Malmgren RA, Holmes EC, et al: Demonstration of antibodies against malignant melanoma by immunofluorescence. Surgery 64:233-240, 1968.
19. Mukherji B, Chakraborty NG, Sivanandham M: T-cell clones that react against autologous human tumors. Immunol Rev 116:33-62, 1990.
20. Tjandrawan T, Martin DM, Maeurer MJ, et al: Autologous human dendriphages pulsed with synthetic or natural tumor peptides elicit tumor-specific CTLs in vitro. J Immunother 2:149-157, 1998.
21. Zajac P, Oertli D, Spagnoli GC, et al: Generation of tumoricidal cytotoxic T lymphocytes from healthy donors after in vitro stimulation with a replication-incompetent vaccinia virus encoding MART-I/Melan-A 27-35 epitope. Int J Cancer 71:491-496, 1997.
22. Livingston PO, Natoli EJ, Calves MJ, et al: Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients. Proc Natl Acad Sci USA 84:2911-2915, 1987.
23. Livingston PO, Ritter G, Srivastava P, et al: Characterization of IgG and IgM antibodies induced in melanoma patients by immunization with purified GM2 ganglioside. Cancer Res 49:7045-7050, 1989.
24. Hoon DS, Yuzuki D, Hayashida M, et al: Melanoma patients immunized with melanoma cell vaccine induce antibody responses to recombinant MAGE-1 antigen. J Immunol 154:730-737, 1995.
25. Morisaki T, Morton DL, Uchiyama A, et al: Characterization and augmentation of CD4+ cytotoxic T cell lines against melanoma. Cancer Immunol Immunother 39:172-178, 1994.
26. Chan A, Morton DL: Active immunotherapy with allogeneic tumor cell vaccines: Present status. Semin Oncol 25:611-622, 1998.
27. a are differentiation antigens immunogenic in human melanoma. Cancer 79:1686-1697, 1997.
28. x and GM3 correlates with tumor growth after immunization with melanoma-cell vaccine with different adjuvants in mice. Int J Cancer 75: 117-124, 1998.
29. Morton DL, Foshag LJ, Hoon DS, et al: Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 216:463-482, 1992.
30. Morton DL, Nizze A, Hoon D, et al: Improved survival of advanced stage IV melanoma following active immunotherapy: Correlation with immune response to melanoma vaccine (abstract). Proc Am Soc Clin Oncol 12:391, 1993.
31. Hsueh EC, Nizze A, Essner R, et al: Adjuvant immunotherapy with polyvalent melanoma cell vaccine (PMCV) prolongs survival after complete resection of distant melanoma metastases (abstract). Proc Am Soc Clin Oncol 16:492, 1997.
32. Hsueh EC, Gupta RK, Qi K, et al: Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine. J Clin Oncol 16:2913-2920, 1998.
33. 32a. Hsueh EC, Nathanson L, Foshag LJ, et al: Active specific immunotherapy with polyvalent melanoma cell vaccine for patients with in-transit melanoma metastases. Cancer 85:2160-2169, 1999,
34. Jones RC, Kelley M, Gupta RK, et al: Immune response to polyvalent melanoma cell vaccine in AJCC stage III melanoma: An immunologic survival model. Ann Surg Oncol 3:437-445, 1996.
35. Morton DL, Eilber FR, Holmes EC, et al: Preliminary results of a randomized trial of adjuvant immunotherapy in patients with malignant melanoma who have lymph node metastases. Aust NZ J Surg 48:49-52, 1978.
36. Cascinelli N, Rumke P, MacKie R, et al: The significance of conversion of skin reactivity to efficacy of bacillus Calmette-Guerin (BCG) vaccinations given immediately after radical surgery in stage II melanoma patients. Cancer Immunol Immunother 28:282-286, 1989.
37. Berd D, Mastrangelo MJ: Active immunotherapy of human melanoma exploiting the immunopotentiating effects of cyclophosphamide. Cancer Invest 6:337-349, 1988.
38. Peters LC, Brandhorst JS, Hanna MG Jr: Preparation of immunotherapeutic autologous tumor cell vaccines from solid tumors. Cancer Res 39:1353-1360, 1979.
39. Berd D, Maguire HC Jr, McCue P, et al: Treatment of metastatic melanoma with an autologous tumor-cell vaccine: Clinical and immunologic results in 64 patients. J Clin Oncol 8:1858-1867, 1990.
40. Berd D, Maguire HC Jr, Schucter LM, et al: Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases. J Clin Oncol 15:2359-2370, 1997.
41. Mitchell MS, Harel W, Kempf RA, et al: Active specific immunotherapy of melanoma. J Clin Oncol 10:1158-1164, 1992.
42. Wallack MK: Specific immunotherapy with vaccinia oncolysates. Cancer Immunol Immunother 12:1-4, 1981.
43. Hersey P: Evaluation of vaccinia viral lysates as therapeutic vaccines in the treatment of melanoma. Ann NY Acad Sci 690:167-177, 1993.
44. Wallack MK, Muthukumaran S, Balch CM, et al: Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: The final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial. J Am Coll Surg 187:69-79, 1998.
45. Roenigk HH Jr, Deodhar S, Jacques RS, et al: Immunotherapy of malignant melanoma with vaccinia virus. Arch Dermatol 109:668-673, 1974.
46. Hersey P: Active immunotherapy with viral lysates of micro-metastases following surgical removal of high-risk melanoma. World J Surg 16:251-260, 1992.
47. Hersey P, Coates A, Tyndall L: Is adjuvant therapy worthwhile? (abstract) Melanoma Res 7:22, 1997.
48. Mitchell MS, Harel W, Kempf RA, et al: Active specific immunotherapy of melanoma. J Clin Oncol 10:1158-1164, 1992.
49. Mitchell MS: Perspective on allogeneic melanoma lysates in active specific immunotherapy. Semin Oncol 25:623-635, 1998.
50. Elliot GT, McLeod RA, Perez J, et al: Interim results of a phase II multicenter clinical trial evaluating the activity of a therapeutic allogeneic melanoma vaccine (theraccine) in the treatment of disseminated malignant melanoma. Semin Surg Oncol 9:264-272, 1993.
51. Mitchell MS, Von Eschen KB: Phase III trial of Melacine melanoma theraccine vs combination chemotherapy in the treatment of stage IV melanoma (abstract). Proc Am Soc Clin Oncol 16:1778, 1997.
52. Bystryn JC: Vaccines for melanoma: Design strategies and clinical results. Dermatol Clin 16:269-275, 1998.
53. Bystryn JC, Oratz R, Roses D, et al: Relation between immune response to melanoma vaccine immunization and clinical outcome in stage II malignant melanoma. Cancer 69:1157-1164, 1992.
54. Bystryn JC, Oratz R, Shapiro RL, et al: Phase III double-blind trial of a shed, polyvalent, melanoma vaccine in stage III melanoma (abstract). Proc Am Soc Clin Oncol 17:434a, 1998.
55. Tai T, Cahan LD, Tsuchida T, et al: Immunogenicity of melanoma-associated gangliosides in cancer patients. Int J Cancer 35:607-612, 1994.
56. Irie RF, Matsuki T, Morton DL: Human monoclonal antibody to ganglioside GM2 for melanoma treatment. Lancet 1:786-787, 1989.
57. Irie RF, Morton DL: Regression of cutaneous metastatic melanoma by intralesional in jection with human monoclonal antibody to ganglioside GD2. Proc Natl Acad Sci USA 83:8694-8698, 1986.
58. Livingston PO, Wong GY, Adluri S, et al: Improved survival in stage III melanoma patients with GM2 antibodies: A randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 12:1036-1044, 1994.
59. Livingston PO: Ganglioside vaccines with emphasis on GM2. Semin Oncol 25:636-645, 1998.
60. Kitamura K, Livingston PO, Fortunato SR, et al: Serological response patterns of melanoma patients immunized with a GM2 ganglioside conjugate vaccine. Proc Natl Acad Sci USA 92:2805-2809, 1995.
61. Tsuchida T, Saxton RE, Morton DL, et al: Gangliosides of human melanoma. J Natl Cancer Inst 78:45-54, 1987.
62. Ravidranath MH, Morton DL, Irie RF: An epitope common to gangliosides O-acetyl-GD3 and GD3 recognized by antibodies in melanoma patients after active specific immunotherapy. Cancer Res 49:3891-3897, 1989.
63. Traversari C, van der-Bruggen P, Luescher IF, et al: A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med 176:1453-1457, 1992.
64. van der-Bruggen P, Bastin J, Gajewski T, et al: A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol 24:3038-3043, 1994.
65. Zhai Y, Yang JC, Kawakami Y, et al: Antigen-specific tumor vaccines: Development and characterization of recombinant adenoviruses encoding MART-1 or gp100 for cancer therapy. J Immunol 156:700-710, 1996.
66. Cormier JN, Salgaller ML, Prevette T, et al: Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART/Melan-A. Cancer J Sci Am 3:37-44, 1997.
67. Takechi Y, Hara I, Naftzger C, et al: A melanosomal membrane protein is a cell surface target for melanoma therapy. Clin Cancer Res 2:1837-1842, 1996.
68. Bakker ABH, Schreurs MWJ, de Boer AJ, et al: Melanocyte lineage specific gp100 is recognized by melanoma derived tumor infiltrating lymphocytes. J Exp Med 179:1005-1009, 1994.
69. Pass HA, Schwarz SL, Wunderlich JR, et al: Immunization of patients with melanoma peptide vaccines: Immunologic assessment using the ELISPOT assay. Cancer J Sci Am 4:316-323, 1998.
70. Wolfel T, Van Pel A, Brichard V, et al: Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur J Immunol 24:759-764, 1994.
71. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al: Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4:321-327, 1998.
72. Marchand M, Weynants P, Rankin E: Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int J Cancer 63:883-885, 1995.
73. Menoret A, Chandawarkar R: Heat-shock protein-based anticancer immunotherapy: An idea whose time has come. Semin Oncol 25:654-660, 1998.
74. Fu TM, Ulmer JB, Caulfield MJ: Priming of cytotoxic T lymphocytes by DNA vaccines: Requirement for professional antigen presenting cells and evidence for antigen transfer from myocytes. Mol Med 3:362-371, 1997.
75. Ulmer JB, Deck RR, DeWitt CM, et al: Expression of a viral protein by muscle cells in vivo induces protective cell-mediated immunity. Vaccine 15:839-841, 1997.
76. Borysiewicz LK, Fiander A, Nimako M, et al: A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 347:1523-1527, 1996.
77. Schreurs MW, de Boer AJ, Figdor CG, et al: Genetic vaccination against the melanocyte lineage-specific antigen gplOO induces cytotoxic T lymphocyte-mediated tumor protection. Cancer Res 58:2509-2514, 1998.
78. Sun T, Carr-Brendel V, De Zoeten EF, et al: Immunization with interleukin-2-secreting allogeneic cells transfected with DNA from mouse melanoma cells induces immune responses that prolong the lives of mice with melanoma. Cancer Gene Ther 5:110-118, 1998.
79. Mayordomo JI, Zorina T, Storkus WJ, et al: Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med 1:1297-1302, 1995.
80. Hsu FJ, Benike C, Fagnoni F, et al: Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 2:52-58, 1996.
81. Gong J, Chen D, Kashiwaba M, et al: Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med 3:558-561, 1997.
82. Nestle FO, Alijagic S, Gilliet M, et al: Vaccination of melanoma patients with peptide-or tumor lysate pulsed dendritic cells. Nat Med 4:328-332, 1998.